The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Female Contraceptives Market Research Report 2024
Synopsis
The global Female Contraceptives market was valued at US$ 18390 million in 2023 and is anticipated to reach US$ 22120 million by 2030, witnessing a CAGR of 2.6% during the forecast period 2024-2030.
North American market for Female Contraceptives is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Female Contraceptives is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Female Contraceptives in Personal use is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Female Contraceptives include Bayer, Mayer Laboratories, Pfizer, Mylan, Teva, Merck, Johnson & Johnson, Lupin Pharmaceuticals and Female Health Company, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Female Contraceptives, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Female Contraceptives.
Report Scope
The Female Contraceptives market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Female Contraceptives market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Female Contraceptives companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Mayer Laboratories
Pfizer
Mylan
Teva
Merck
Johnson & Johnson
Lupin Pharmaceuticals
Female Health Company
Fuji Latex
Segment by Type
Contraceptive Drugs
Contraceptive Devices
Segment by Application
Personal use
Hospital
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Female Contraceptives companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Female Contraceptives market was valued at US$ 18390 million in 2023 and is anticipated to reach US$ 22120 million by 2030, witnessing a CAGR of 2.6% during the forecast period 2024-2030.
North American market for Female Contraceptives is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Female Contraceptives is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Female Contraceptives in Personal use is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Female Contraceptives include Bayer, Mayer Laboratories, Pfizer, Mylan, Teva, Merck, Johnson & Johnson, Lupin Pharmaceuticals and Female Health Company, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Female Contraceptives, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Female Contraceptives.
Report Scope
The Female Contraceptives market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Female Contraceptives market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Female Contraceptives companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Mayer Laboratories
Pfizer
Mylan
Teva
Merck
Johnson & Johnson
Lupin Pharmaceuticals
Female Health Company
Fuji Latex
Segment by Type
Contraceptive Drugs
Contraceptive Devices
Segment by Application
Personal use
Hospital
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Female Contraceptives companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Female Contraceptives Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Contraceptive Drugs
1.2.3 Contraceptive Devices
1.3 Market by Application
1.3.1 Global Female Contraceptives Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Personal use
1.3.3 Hospital
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Female Contraceptives Market Perspective (2019-2030)
2.2 Female Contraceptives Growth Trends by Region
2.2.1 Global Female Contraceptives Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Female Contraceptives Historic Market Size by Region (2019-2024)
2.2.3 Female Contraceptives Forecasted Market Size by Region (2025-2030)
2.3 Female Contraceptives Market Dynamics
2.3.1 Female Contraceptives Industry Trends
2.3.2 Female Contraceptives Market Drivers
2.3.3 Female Contraceptives Market Challenges
2.3.4 Female Contraceptives Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Female Contraceptives Players by Revenue
3.1.1 Global Top Female Contraceptives Players by Revenue (2019-2024)
3.1.2 Global Female Contraceptives Revenue Market Share by Players (2019-2024)
3.2 Global Female Contraceptives Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Female Contraceptives Revenue
3.4 Global Female Contraceptives Market Concentration Ratio
3.4.1 Global Female Contraceptives Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Female Contraceptives Revenue in 2023
3.5 Female Contraceptives Key Players Head office and Area Served
3.6 Key Players Female Contraceptives Product Solution and Service
3.7 Date of Enter into Female Contraceptives Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Female Contraceptives Breakdown Data by Type
4.1 Global Female Contraceptives Historic Market Size by Type (2019-2024)
4.2 Global Female Contraceptives Forecasted Market Size by Type (2025-2030)
5 Female Contraceptives Breakdown Data by Application
5.1 Global Female Contraceptives Historic Market Size by Application (2019-2024)
5.2 Global Female Contraceptives Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Female Contraceptives Market Size (2019-2030)
6.2 North America Female Contraceptives Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Female Contraceptives Market Size by Country (2019-2024)
6.4 North America Female Contraceptives Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Female Contraceptives Market Size (2019-2030)
7.2 Europe Female Contraceptives Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Female Contraceptives Market Size by Country (2019-2024)
7.4 Europe Female Contraceptives Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Female Contraceptives Market Size (2019-2030)
8.2 Asia-Pacific Female Contraceptives Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Female Contraceptives Market Size by Region (2019-2024)
8.4 Asia-Pacific Female Contraceptives Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Female Contraceptives Market Size (2019-2030)
9.2 Latin America Female Contraceptives Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Female Contraceptives Market Size by Country (2019-2024)
9.4 Latin America Female Contraceptives Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Female Contraceptives Market Size (2019-2030)
10.2 Middle East & Africa Female Contraceptives Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Female Contraceptives Market Size by Country (2019-2024)
10.4 Middle East & Africa Female Contraceptives Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Detail
11.1.2 Bayer Business Overview
11.1.3 Bayer Female Contraceptives Introduction
11.1.4 Bayer Revenue in Female Contraceptives Business (2019-2024)
11.1.5 Bayer Recent Development
11.2 Mayer Laboratories
11.2.1 Mayer Laboratories Company Detail
11.2.2 Mayer Laboratories Business Overview
11.2.3 Mayer Laboratories Female Contraceptives Introduction
11.2.4 Mayer Laboratories Revenue in Female Contraceptives Business (2019-2024)
11.2.5 Mayer Laboratories Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Female Contraceptives Introduction
11.3.4 Pfizer Revenue in Female Contraceptives Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Mylan
11.4.1 Mylan Company Detail
11.4.2 Mylan Business Overview
11.4.3 Mylan Female Contraceptives Introduction
11.4.4 Mylan Revenue in Female Contraceptives Business (2019-2024)
11.4.5 Mylan Recent Development
11.5 Teva
11.5.1 Teva Company Detail
11.5.2 Teva Business Overview
11.5.3 Teva Female Contraceptives Introduction
11.5.4 Teva Revenue in Female Contraceptives Business (2019-2024)
11.5.5 Teva Recent Development
11.6 Merck
11.6.1 Merck Company Detail
11.6.2 Merck Business Overview
11.6.3 Merck Female Contraceptives Introduction
11.6.4 Merck Revenue in Female Contraceptives Business (2019-2024)
11.6.5 Merck Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Female Contraceptives Introduction
11.7.4 Johnson & Johnson Revenue in Female Contraceptives Business (2019-2024)
11.7.5 Johnson & Johnson Recent Development
11.8 Lupin Pharmaceuticals
11.8.1 Lupin Pharmaceuticals Company Detail
11.8.2 Lupin Pharmaceuticals Business Overview
11.8.3 Lupin Pharmaceuticals Female Contraceptives Introduction
11.8.4 Lupin Pharmaceuticals Revenue in Female Contraceptives Business (2019-2024)
11.8.5 Lupin Pharmaceuticals Recent Development
11.9 Female Health Company
11.9.1 Female Health Company Company Detail
11.9.2 Female Health Company Business Overview
11.9.3 Female Health Company Female Contraceptives Introduction
11.9.4 Female Health Company Revenue in Female Contraceptives Business (2019-2024)
11.9.5 Female Health Company Recent Development
11.10 Fuji Latex
11.10.1 Fuji Latex Company Detail
11.10.2 Fuji Latex Business Overview
11.10.3 Fuji Latex Female Contraceptives Introduction
11.10.4 Fuji Latex Revenue in Female Contraceptives Business (2019-2024)
11.10.5 Fuji Latex Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
